Hanyang University Medical Center

Seoul, Korea 04763

0 studies enrolling now · 7 studies all time

What they study most

Atopic Dermatitis, Psoriasis, Rheumatoid Arthritis, Systemic Lupus Erythematosus

Studies at this site

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) — Completed
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) — Stopped early
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) — Completed
• An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis — Completed